Nirek. Announces Positive Results From Gosselin Vein Property

Ontario, Canada – November 02,2007 – Nirek Resources Inc. (“Nirek”) (Frankfurt: 3N6-FRA) is pleased to announce that initial assays from the Gosselin Vein property in the Shining Tree area have returned positive results of presence of gold veins.

The Phase 1 Exploration Program, which started September 25, 2007, consisted of line cutting and survey control, geological mapping, geo-chemical soil sampling and rock chip sampling, geophysics (magnetometry and IP), pitting of anomalous areas and follow-up diamond drilling. The initial assays of rock sample results from Swastika Laboratories Ltd. have certified samples that show gold content as high as 2.28 grams/ton of gold. All of the samples returned presence of gold. There was also strong presence of silver and copper in the assay samples.

All previous assumptions and interpretations will be re-evaluated to establish a property wide framework for potential mineralization. This will entail a combination of field examinations and data review of the many known showings on the property, integrated with a detailed geophysical interpretation of significant structures. A geologist was on site this week and will be preparing a report.

The principle objective of Nirek Resources Inc. is to enhance and develop known mineral properties to production potential.

The company is well financed to continue its exploration program into 2008.

Nirek Resources Inc. (“NIREK”) is a Canadian exploration company focused on exploring for precious and base metals in US and Canada. Its goal is to become one of Canada’s major gold and precious metals producers through a series of joint ventures and mine and property acquisitions.  It is the company’s ambition to fulfill drilling requirements necessary to estimate a NI 43-101 compliant resource.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies or products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.